Objective:To study the dynamic changes of α-melanocyte stimulating hormone (α-MSH) and S100B calcium binding protein in patients with blunt chest trauma and its correlation with disease prognosis. Methods:42 patients with blunt chest trauma and 42 cases of the control group (health check) were collected in our hospital from May 2014 to January 2016. The contents of α-MSH, S100B and tumor necrosis factor-α(TNF-α) in the serum on admission and at 1 d, 4 d, and 7 d after admission were detected by ELISA. In the blunt chest trauma patients and control group, the expression levels of each index in serum were analysed, the sensitivity and specificity of each indicator in blunt chest trauma disease were determined by receiver operating characteristic(ROC). Finally, the correlation of the prognosis of the patients with α-MSH and S100B was analyzed. Results:The level of serum α-MSH in the patients with blunt chest trauma was significantly lower than that in the control group (F=17.236, P=0.036), and the levels of α-MSH were first decreased and then increased with the duration of the disease. The levels of S100B and TNF-α in patients serum were the same as that of α-MSH. It increased at first and then decreased with the prolongation of the course of disease. It reached the peak value when the patient was admitted to 1 d. In the patients with blunt chest trauma, the area under curve of the serum α-MSH, S100B, and TNF-α in the ROC curve was 0.848, 0.748, and 0.633, respectively. Compared with the control group, the quality of life of patients with blunt chest trauma decreased (P<0.05), and the correlation analysis showed that the α-MSH and S100B protein were closely related to the quality of life of patients with blunt chest trauma. Conclusion:The level of serum α-MSH and S100B protein in patients with blunt chest trauma can reflect the development of the disease, and which is closely related to the quality of life of patients. It is of great significance for early monitoring and evaluation of blunt chest trauma in clinic.
 BOHM M,APEL M,LOWIN T,et al.Alpha-MSH modulates cell adhesion and inflammatory responses of synovial fibroblasts from osteoarthritis patients[J].Biochem Pharmacol,2016,116:89-99.
 OTTANI A,NERI L,CANALINI F,et al.Protective effects of the melanocortin analog NDP-alpha-MSH in rats undergoing cardiac arrest[J].Eur J Pharmacol,2014,745:108-116.
 KUMAR P,WILLIAM J N,DURKIN K L,et al.Neuropeptide alpha-MSH exerts pro-inflammatory effects on Neisseria meningitidis infection in vitro[J].Inflamm Res,2010,59(2):105-113.
 SCHULTE H O,QUARCOO D,BRZOSKA T,et al.Alpha-MSH promotes spontaneous post-ischemic pneumonia in mice via melanocortin-receptor-1[J].Exp Neurol,2008,210(2):731-739.
 YAMAOKA T M,TOJO T,SHIOI T,et al.Central neurotranspeptide,alpha-melanocyte-stimulating hormone (alpha-MSH) is upregulated in patients with congestive heart failure[J].Intern Med,2006,45(7):429-434.
 DUMONT A O,GOURSAUD S,DESMET N,et al.Differential regulation of glutamate transporter subtypes by pro-inflammatory cytokine TNF-alpha in cortical astrocytes from a rat model of amyotrophic lateral sclerosis[J].PLoS One,2014,9(5):e97649.
 OTTANI A,GIULIANI D,NERI L,et al.NDP-alpha-MSH attenuates heart and liver responses to myocardial reperfusion via the vagus nerve and JAK/ERK/STAT signaling[J].Eur J Pharmacol,2015,769:22-32.